Publications by authors named "A Wirsching"
Objectives: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy can induce long-term drug-free remission in patients with autoimmune diseases (AIDs). The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo.
Methods: Sequential ultrasound-guided inguinal lymph node biopsies were performed at baseline and after CD19-CAR T-cell therapy in patients with AIDs.
Impact of the digital health application ViViRA on spinal mobility, physical function, quality of life and pain perception in spondyloarthritides patients: a randomized controlled trial.
Arthritis Res Ther
December 2024
Article Synopsis
- Spondyloarthritides (SpAs) are rheumatic diseases causing lower back pain and limited mobility, and access to physiotherapy is often a barrier to effective treatment.
- A study compared the digital health application ViViRA with standard physiotherapy among SpAs patients, assessing pain, quality of life, and mobility over 12 weeks.
- Results showed that the ViViRA group had better mobility improvements and lower pain intensity compared to the control group, indicating that digital health applications may be more effective than traditional physiotherapy for treating lower back pain in these patients.
Background: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has shown remarkable outcomes in patients with systemic lupus erythematosus. The effects of CD19-targeting CAR T cells on organ manifestations in patients with systemic sclerosis have yet to be characterised. B cells have a central role in the pathogenesis of systemic sclerosis.
View Article and Find Full Text PDF